Welcome to our dedicated page for PFIZER SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
PFIZER INC (symbol: PFE) is the issuer of record for a Form 4 filing submitted to the SEC. BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC (PFE) reported that Chairman & CEO Albert Bourla received an award of 22 Phantom Stock Units SSP on September 15, 2026. Each unit represents one phantom share of common stock and was valued at $27.55 per unit, increasing his directly held phantom stock units to 783,985. The units were granted under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and will be settled in cash following his separation from service, with flexibility to transfer them into an alternative investment account at any time.
PFIZER INC (symbol: PFE) is the issuer of record for a Form 4 filing submitted to the SEC.
PFIZER INC (PFE) reported the initial holdings of Executive Vice President Cecile Guegan on a Form 3. She directly owns 149,505 shares of Pfizer common stock. She also holds multiple Stock Appreciation Rights (SARs) over Pfizer common stock, including SARs with exercise prices of $25.75 on 33,051 underlying shares expiring on March 4, 2030, and SARs with exercise prices of $26.58, $26.89, $31.31, $33.82, $42.30 and $45.96 over various numbers of underlying shares, expiring between 2027 and 2031. Footnotes state these SARs are subject to vesting and will be settled in Pfizer common stock on either the fifth or seventh anniversary of the grant date.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC (PFE) reported that Chairman & CEO Albert Bourla received an award of 22 Phantom Stock Units SSP on 2026-08-14. Each unit represents one phantom share of common stock and is valued at $26.79 per unit. Following this grant, Bourla holds 785,060 Phantom Stock Units, which are cash-settled under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan after his separation from service and may be reallocated into alternative investment accounts.
Pfizer Inc., as an institutional investment manager, submitted a quarterly Form 13F holdings report covering its reportable equity investment positions. The report lists 20 individual holdings with a combined reported value of $170,365,906, rounded to the nearest dollar.
The report is signed by Madelyn D. Purcell, Assistant General Counsel, who represents that the information provided is true, correct, and complete. No other investment managers are included in this filing.
Pfizer Inc. Chairman & CEO Albert Bourla reported an open-market purchase of 38,000 shares of Pfizer common stock on 2026-08-12 at $26.34 per share. Following this transaction, he holds 429,173 shares directly and 6,382 shares indirectly through a Rule 16b-3 Plan.
Pfizer Inc officer Jennifer B. D'Amico, SVP & Controller, reported a sale of 3,278 shares of Common Stock on 2026-08-05 at $25.40 per share. Following this open market or private transaction, she directly held 28,611 Pfizer shares.
Pfizer Inc. director Ronald E. Blaylock purchased 39,231 shares of Common Stock on August 5, 2026 at $25.46 per share in an open market or private transaction. After this buy, he directly holds 66,938 shares and indirectly holds 4,750 shares by trust. The trade was not made under a Rule 10b5-1 plan.
Pfizer Inc. director Mortimer J. Buckley purchased 37,632 shares of common stock on August 5, 2026, in a transaction reported as a purchase in open market or private transaction at $25.52 per share. After this buy, he directly holds 37,632 Pfizer common shares.
Pfizer Inc. reported Q2 2026 revenues of $15,034 million, slightly above $14,653 million a year earlier, but swung to a net loss attributable to common shareholders of $(248) million, or $(0.04) per basic and diluted share, versus earnings of $0.51. Results were heavily affected by $4,325 million of intangible asset impairments, mainly $3,800 million for an IPR&D asset (sigvotatug vedotin) after unfavorable Phase 3 results and $525 million for Oxbryta developed technology rights, partially offset by a $1,870 million gain on sale of the ViiV stake.
For the first six months of 2026, revenues were $29,484 million and net income attributable to common shareholders was $2,440 million, or $0.43 per share, compared with $28,367 million and $5,877 million in 2025. Operating cash flow improved to $3,450 million. Long-term debt was $60,495 million and total equity $85,492 million at June 28, 2026.
Pfizer highlighted strategic actions including the $8.0 billion Metsera acquisition, adding $7.9 billion of IPR&D and $2.1 billion of goodwill, the completion of its exit from ViiV for $1,875 million in cash, a Sciwind ecnoglutide in-licensing deal with up to $495 million in potential milestones, and large multi-year cost realignment and manufacturing optimization programs with expected aggregate one-time costs of $12.7 billion and cumulative spending to date of $4.9 billion and $1.1 billion, respectively.